These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1031037)

  • 1. [The use of an injectable anti-aldosteron agent in the treatment of secondary hyperaldosteronism].
    Tartagni F; Ambrosioni E
    Boll Soc Ital Cardiol; 1976; 21(4):725-7. PubMed ID: 1031037
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effectiveness of K canrenoate in the treatment of secondary hyperaldosteronism].
    Tartagni F; Pasetti L; Ambrosioni E; Magnani B
    G Clin Med; 1979 Mar; 60(3):196-206. PubMed ID: 520727
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of an aldosterone antagonist in abdominal surgery].
    Ribero F; Remonda G; Morachioli N; Pugnani M
    Ann Osp Maria Vittoria Torino; 1982; 25(1-6):61-70. PubMed ID: 7185311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
    Coltorti M; Radaeli E; Ciaccio S; Corsini R; Trebbi R
    Clin Ter; 1976 Feb; 76(3):215-34. PubMed ID: 963962
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
    Gorbach HC; Bräuninger HJ
    MMW Munch Med Wochenschr; 1975 Sep; 117(37):1483-6. PubMed ID: 810673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation].
    Denis B; Dimitriou R; Machecourt J; Wolf JE; Page E; Reboud JP
    Arch Mal Coeur Vaiss; 1984 Apr; 77 Spec No():35-40. PubMed ID: 6428361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Potassium canreonate in neurosurgical brain edema].
    Mille T; Rodriguez R; Baena Y
    Minerva Chir; 1975 Jul 15-31; 30(13-14):781-9. PubMed ID: 1221307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of digitalis toxicity with intravenous potassium canrenoate.
    Gavrilescu G; Cristodorescu R; Deutsch G; Berger E
    Agressologie; 1977; 18(3):167-71. PubMed ID: 920909
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy of canrenoate potassium in hypertensive cardiopathy. Clinical and echocardiographic evaluation].
    Caporicci D; Achilli L
    Minerva Cardioangiol; 1984 Sep; 32(9):581-7. PubMed ID: 6514202
    [No Abstract]   [Full Text] [Related]  

  • 10. [Changes in nitrogen balance during the period following abdominal surgery and use of an injectable anti-aldosterone].
    Metivier Y; Guinot P; Saizy R; Meillaud J; Lioret N
    Agressologie; 1976; 17(5):313-8. PubMed ID: 1015551
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of potassium canrenoate in cardiosurgery].
    Tufano R; Scopa M; Brando G; Leone D
    Minerva Anestesiol; 1981 Apr; 47(4):149-54. PubMed ID: 7242963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Brain edema in neurosurgery. Trial with an aldosterone-antagonist (soldactone) (author's transl)].
    Anderes JP; de Tribolet N; Zander E
    Schweiz Rundsch Med Prax; 1977 Aug; 66(32):1020-6. PubMed ID: 556440
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of canrenoate potassium given orally in ascitogenic cirrhosis].
    Sarti F; Milandri GL; Piemontese A; Macchia S; Simoni S; Dal Monte PR
    Minerva Dietol Gastroenterol; 1984; 30(3):273-80. PubMed ID: 6504377
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of canrenoate potassium on intraoperative disturbances of electrolyte equilibrium].
    Eschner J; Fodor L; Ahnefeld FW
    Infusionsther Klin Ernahr; 1976 Apr; 3(2):98-104. PubMed ID: 965083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
    Consolo F; Ferraù O; Pitrone F; Luzza G; Russo A; Virga T
    Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1943-9. PubMed ID: 1231877
    [No Abstract]   [Full Text] [Related]  

  • 17. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
    Costa FV; Borghi C; Mussi A; Ambrosioni E
    Minerva Cardioangiol; 1988 Oct; 36(10):503-7. PubMed ID: 3226562
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of potassium canrenoate on arterial pressure, plasma renin activity and urinary aldosterone in essential hypertension].
    Opocher G; Armanini D; Fallo F; Mantero F
    Boll Soc Ital Cardiol; 1978; 23(10):1757-66. PubMed ID: 400390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.